Quantcast
Home > Quotes > CTXR

Citius Pharmaceuticals, Inc. Common Stock (CTXR) Quote & Summary Data

CTXR 
$1.17
*  
0.12
11.43%
Get CTXR Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading CTXR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 1.20 / $ 1.10
Share Volume
396,600
50 Day Avg. Daily Volume
139,876
Previous Close
$ 1.05
52 Week High / Low
$ 4 / $ 0.8582
Market Cap
20,824,585
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.05

Intraday Chart

Shares Traded

Share Volume:
396,600
50 Day Avg. Daily Volume:
139,876

Trading Range

The current last sale of $1.17 is 36.33% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.20 $ 4
 Low: $ 1.10 $ 0.8582

Company Description (as filed with the SEC)

Citius Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting important medical needs with a focus on anti-infective products in adjunct cancer care and unique prescription products. Our goal is to achieve leading market positions by providing therapeutic products that address unmet medical needs yet have a lower development risk than is associated with new chemical entities. New formulations or combinations of previously approved drugs with substantial existing safety and efficacy data are a core focus as we seek to reduce development and clinical risks associated with drug development. Our strategy centers on products that have intellectual property and regulatory exclusivity protection, while providing competitive advantages over other existing therapeutic approaches.  ... More ...  


Risk Grade

Where does CTXR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.11
Open Date:
Feb. 15, 2019
Close Price:
$ 1.17
Close Date:
Feb. 15, 2019

Consensus Recommendation

Analyst Info